FDA sends a warning about perioperative cancer studies
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
ESMO 2024 preview – Summit and BioNTech battle again
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
ESMO 2024 preview – Astellas unveils its KRAS degrader
ASP3082 grabs some early attention among degraders set to feature at ESMO.
ESMO 2024 preview – conjugates in the spotlight
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
No shortcuts for Agenus
The FDA throws out the company’s second attempt at an accelerated approval.
